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Abstract  
Context: The present systematic review and meta-analysis aims to perform an extensive search in databases 
to compare the efficacy of the intranasal administration of naloxone with its intramuscular/intravenous 
administration in the pre-hospital management of opioid overdose.  
Evidence acquisition: This meta-analysis included controlled trials conducted on the efficacy of naloxone 
administration in the pre-hospital management of opioid overdose. A search was carried out in electronic 
databases on relevant articles published by the end of 2018. After data collection, analyses were performed in 
STATA 14.0 software and the efficacy and side-effects of the two administration routes of naloxone, i.e. 
intranasal and intramuscular/intravenous, were compared. An overall effect size with 95% confidence interval 
(95% CI) was provided for each section.   
Results: Eventually, data from six studies were included in this meta-analysis. The success rate of the intranasal 
and intramuscular/intravenous administration of naloxone in the management of opioid overdose in pre-
hospital settings was 82.54% (95% CI: 57.97 to 97.89%) and 80.39% (95% CI: 57.38 to 96.04%), respectively. 
There was no difference between injectable (intramuscular/intravenous) naloxone and intranasal naloxone in 
the pre-hospital management of opioid overdose (Odds Ratio=1.01; 95% CI: 0.42 to 2.43; P=0.98). The onset of 
action of intranasal naloxone, however, was slightly longer than injectable naloxone (Standardized Mean 
Difference=0.63; 95% CI: 0.07 to 1.19; P=0.03). Additionally, the odds of needing a rescue dose was 2.17 times 
higher for intranasal naloxone than intramuscular/intravenous naloxone (OR=2.17; 95% CI: 1.53 to 3.09; 
P<0.0001). The prevalence of major side-effects was non-significant for both intranasal (0.00%) and 
intramuscular/intravenous (0.05%) routes of naloxone administration and there was no difference in the 
prevalence of major (OR=1.18; 95% CI: 0.38 to 3.69; P=0.777) and minor (OR=0.64; 95% CI: 0.17 to 2.34; 
P=0.497) side-effects between the two routes.  
Conclusion: The present meta-analysis demonstrated that intranasal naloxone is as effective as injectable 
naloxone in the pre-hospital management of opioid overdose complications. Consequently, intranasal 
naloxone may be an appropriate alternative to injectable naloxone. 
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CONTEXT  
Opioid overdose is one of the most common causes 
of death and disability worldwide. Statistics 
suggest that the prevalence of complications of 
opioid overdose is increasing in various societies 
and the number of emergency medical service calls 
and hospital referrals related to this disorder has 
increased dramatically (1, 2). According to the 
existing guidelines, naloxone is prescribed for the 
treatment of opioid overdose. Nonetheless, the 
majority of these guidelines are designed for in-
hospital settings, and there are still questions 
regarding the use of naloxone in pre-hospital 
settings. For instance, the optimum routes and 
dosage for naloxone administration in the pre-
hospital management of opioid overdose 
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complications are still unclear. Research in this 
area thus continues.  
In recent years, numerous clinical trials have 
investigated the administration of naloxone for the 
pre-hospital management of opioid overdose 
complications. As an example, Kelly et al. 
demonstrated that, in the first ten minutes of 
administration, the success rate of intravenous 
naloxone is more than intranasal naloxone in the 
management of respiratory depression symptoms 
of opioid overdose (3). In another study, Kerr et al. 
displayed that the intranasal and intramuscular 
administration of naloxone have the same efficacy 
in the management of opioid overdose 
complications. Nevertheless, it seems that a rescue 
dose is less needed in intramuscular than 
intranasal administration (4). These 
inconsistencies in studies led Cho et al. to conduct 
a systematic review about the subject. Their 
findings revealed that high-dose intranasal 
naloxone may have a similar efficacy to 
intramuscular naloxone (5). Meanwhile, 
limitations such as not performing a meta-analysis 
and not including the records of the Embase 
database may have resulted in a potential bias in 
their findings. Considering the limitations of 
previous studies, the present systematic review 
and meta-analysis aims to carry out an extensive 
search in databases to compare the efficacy of 
intranasal and intramuscular/intravenous 
naloxone in the pre-hospital management of opioid 
overdose complications. 
EVIDENCE ACQUISITION 
Study design 
The present review intends to answer the following 
three questions: 
1. What would be the optimum route for 
naloxone in pre-hospital settings to manage 
opioid overdose symptoms? 
2. What is the optimum dose of naloxone needed 
for the management of opioid overdose 
complications in pre-hospital settings? 
3. What side-effects would naloxone, 
administered for the management of opioid 
overdose complications, cause in pre-hospital 
settings? 
To answer these questions, a comprehensive 
search was carried out in electronic databases for 
articles published by the end of 2018. The study 
was designed based on the Cochrane meta-analysis 
guidelines for clinical trials and its method is 
similar to the one used in the other systematic 
reviews conducted by the present article’s authors 
(6-18). Panel 1 presents the PICO for the study.  
Search strategy 
Initially, several keywords were selected upon the 
advice of toxicologists and emergency medicine 
specialists. These words were then searched in 
MeSH and Emtree and the related words and 
synonyms found were added to the search strategy. 
Other related words were added by screening the 
titles and abstracts of any relevant articles. All 
keywords were related to opioid overdose and 
naloxone. Afterwards, a comprehensive search was 
carried out in Medline, Embase, Scopus, CENTRAL 
and Web of Science for articles published by the 
end of 2018. Appendix 1 presents the search 
strategy in Medline database. In addition to the 
systematic search, a manual search was also 
performed in Google search engine, and Google 
Scholar and the articles noted in the bibliography 
of the retrieved articles were also examined. 
Eligibility criteria  
Prospective clinical trials and cohorts conducted 
on adult patients were included in the present 
study. The absence of data on the route and doses 
of naloxone administration, being conducted in 
hospital settings and being a review article were 
taken as the exclusion criteria. 
Data synthesis and quality assessment 
At first, a researcher conducted a search in the 
noted databases using proper keyword 
combinations and standard tags. The search results 
were then added to EndNote program and 
duplicates were omitted. The records obtained 
were then handed over to two other researchers so 
that the results would be independently screened 
based on their titles and abstracts. The full texts of 
the selected records were adopted and eventually 
the relevant articles were summarized in a 
checklist designed based on PRISMA protocols. The 
data entered into the checklist consisted of the first 
author’s name, year of publication, patients’ 
characteristics, route of naloxone administration, 
dose of injection and outcomes. All these steps 
Panel 1: PICO definitions of the study 
PICO Definition 
Problem (P) Opioid overdose in prehospital settings 
Intervention (I) Intranasal naloxone administration 
Comparison (C) Intramuscular/intravenous naloxone administration 
Outcome (O) Success rate, onset of action and complications 
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were completed independently. Any disagreement 
was resolved through discussion (19).  
If the required data were not presented in the 
paper or could not be extracted from its content, a 
request for data was emailed to its authors. In the 
case of no response to the first email, a reminder 
was sent. If there was still no response, a second 
reminder was sent within a week. At last, other 
authors were contacted via social media such as 
ResearchGate and LinkedIn to obtain the data. only 
one of the articles included underwent this step.  
The quality assessment of the studies was carried 
out with the aid of Cochrane’s suggested guidelines. 
Inter-rater reliability was evaluated to assess the 
two researchers’ agreement and any disagreement 
was resolved through discussions with a third 
researcher. 
Statistical Analysis 
The analyses were carried out in STATA 14.0. An 
analysis was conducted separately for each 
outcome, which consisted of the success rate of 
naloxone in opioid overdose symptom 
management, the onset of action of naloxone and 
its side-effects. Depending on the presence or 
absence of heterogeneity, either the random effects 
model or fixed effects model were used. In order to 
evaluate heterogeneity, I2 was performed. 
Eventually, the studies were pooled and an overall 
effect size with 95% confidence interval (CI 95%) 
was presented. It is worth noting that the meta-
analyses were conducted under the condition that 
the data were reported in at least three different 
studies. Funnel plots were used to investigate 
publication bias using Egger’s tests (20). 
RESULTS 
Studies’ characteristics 
The systematic search conducted in this study 
resulted in a total of 1195 records. After omitting 
the duplicates, 775 records were screened; 84 of 
the eligible records, which were mainly cross-
sectional studies or case reports, were studied in 
detail. Eventually, six studies were included in the 
study, including four clinical trials and two cohort 
studies. The studies contained data on 965 patients 
suspected of opioid overdose (4, 21-25). All of 
these patients had been treated with naloxone. In 
the control groups, the patients were treated with 
intravenous (21, 23-25) or intramuscular (4, 22) 
naloxone. In the treatment groups, intranasal 
naloxone was administered to the patients. The 
prescribed dosage for intranasal administration 
was 2 mg. Figure 1 demonstrates the search 
flowchart and study selection process. Table 1 
presents the characteristics of the included studies.  
Quality assessment of the studies and 
publication bias 
The quality assessment of the records was 
performed based on the Cochrane guidelines. As 
illustrated in table 2 and figure 2-A, the risk of bias 
 
Figure 1: PRISMA flow diagram of the meta-analysis 
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in matching the patients (five articles; 83.33%), 
meeting the inclusion and exclusion criteria (six 
articles; 100%), incomplete outcome data (six 
articles; 100%) and selective reporting (six 
articles; 100%) was low in the majority of the 
studies. In contrast, the risk of bias was high in 
allocation concealment (five articles; 83.33%), 
blinding of the patients (five articles; 83.33%) and 
blinding of the outcome assessment (five articles; 
83.33%) in most of the studies. No publication bias 
was observed in the assessment of the therapeutic 
success rate of intranasal naloxone compared to 
intramuscular/intravenous naloxone in managing 
opioid overdose signs and symptoms (Bias 
Table 1: Characteristics of the included studies 
Author; year; 
country 
Study design 
Number 
of 
patients 
treatment 
/ control 
Sampling 
method 
Age Male 
Control 
group 
IN 
naloxon
e group 
Assessed 
outcome 
Barton; 2005; 
USA 
Non-
randomized 
trial 
43 / 9 Consecutive >14 NR IV, 2 mg 2 mg 
Success rate; onset 
of action; need for 
rescue dose; drug-
related side-effects 
Kelly; 2005; 
Australia 
RCT 84 / 71 Convenience 13 to 57 111 IM, 2 mg 2 mg 
Success rate; onset 
of action; need for 
rescue dose; drug-
related side-effects 
Kerr; 2005; 
Australia 
RCT 83 / 89 Convenience 13 to 57 127 IM, 2 mg 2 mg 
Success rate; onset 
of action; need for 
rescue dose; drug-
related side-effects 
Merlin; 2010; 
USA 
Historical 
cohort 
38 / 55 Consecutive 27 to 54 60 IV, 1 to 2 mg 2 mg Success rate 
Robertson; 
2009; USA 
Historical 
cohort 
50 / 104 Consecutive 3 to 06 98 IV, 2 mg 2 mg 
Success rate; onset 
of action; need for 
rescue dose 
Sabzghabaee; 
2014; Iran 
RCT 50 / 50 Convenience 15 to 50 76 IV, 0.4 mg 0.4 mg 
Success rate; onset 
of action; drug-
related side-effects 
IM: Intramuscular; IN: Intranasal; IV: Intravenous; NR: Not reported; RCT: Randomized clinical trial 
 
Table 2: Assessing the risk of bias in the included studies 
: High risk of bias 
: Low risk of bias 
: Unclear risk of bias 
B
a
rto
n
; 2
0
0
5
 
K
e
lly
; 2
0
0
5
 
K
e
rr; 2
0
0
5
 
M
e
rlin
; 2
0
1
0
 
R
o
b
e
rtso
n
; 
2
0
0
9
 
S
a
b
zg
h
a
b
a
e
e
; 
2
0
1
4
 
Random sequence generation       
Allocation concealment       
Matching the patients       
Meeting the inclusion and exclusion criteria       
Blinding of the patients       
Blinding of the outcome assessment       
Incomplete outcome data       
Selective reporting       
Other bias       
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Coefficient=-0.11; P=0.93). No publication bias was 
observed in assessing the onset of action of 
naloxone either (Bias Coefficient=3.59, P=0.58). 
Lastly, no publication bias was noted in the 
evaluation of the prevalence of naloxone side-
effects (Bias Coefficient= 4.62; P=0.37); (Figures 2-
B to 2-D).  
Meta-analysis 
 A comparison of the therapeutic success rate of 
naloxone in the management of opioid 
overdose  
All the six articles reported the therapeutic success 
rate of naloxone in the management of the opioid 
overdose, which is defined as the recovery of 
patients’ consciousness and spontaneous 
respiration. The analyses indicated that intranasal 
naloxone controlled the complications of opioid 
overdose in pre-hospital settings in 82.54% (95% 
CI: 57.97 to 97.89%) of the cases and facilitated the 
return of normal respiration and consciousness. 
Also, the therapeutic success rate of the 
intravenous/intramuscular form was 80.39% 
(95% CI: 57.38 to 96.04%). There was no 
difference between intranasal naloxone and 
intramuscular/intravenous naloxone in the 
management of opioid overdose complications 
(OR=1.01; 95% CI: 0.42 to 2.43; P=0.98); (Figures 
3-A to 3-C). 
 Onset of action of naloxone 
Five studies attempted to evaluate the onset of 
action of intranasal and 
intramuscular/intravenous naloxone 
administration. The findings showed that the time 
required to observe a response to intranasal 
naloxone is slightly longer than that for 
intramuscular/intravenous naloxone (SMD=0.63; 
95% CI: 0.07 to 1.19; P=0.03]. Nonetheless, 
although the observed difference is statistically 
significant, the SMD is weak and the finding may 
therefore not be clinically significant (Figure 3-D). 
 The efficacy of naloxone in respiratory 
depression recovery after opioid overdose 
 
Figure 2: The risk of bias (A) and publication bias in the assessment of naloxone success rate (B), onset of action of naloxone (C) and 
naloxone-related complications (D). Coef.: Egger’s test coefficient; OR: Odds ratio; SMD: Standardized mean difference. 
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Three studies evaluated the efficacy of naloxone in 
the management of respiratory depression caused 
by opioid overdose. The findings of these three 
studies indicate that intranasal naloxone improved 
respiratory depression and restored normal 
respiration in 93.63% (95% CI: 60.17 to 100.0%) 
of the patients. This rate was 96.93% (95% CI: 
81.11 to 100.0%) for intramuscular/intravenous 
naloxone. A comparison of the success rate of 
naloxone in the management of respiratory 
depression in the two groups revealed that the 
efficacy of intramuscular/intravenous naloxone 
was slightly better compared to the intranasal 
route (OR=0.42; 95% CI: 0.21 to 0.85; P=0.016); 
(Table 3). 
 The efficacy of naloxone in the recovery of 
consciousness following opioid overdose 
Three studies evaluated the efficacy of naloxone in 
the recovery of consciousness following opioid 
overdose. According to their findings, intranasal 
naloxone increased the level of consciousness in 
83.95% (95% CI: 47.85 to 100.0%) of the cases and 
altered their coma and stupor to obtundation (GCS 
above 11). This rate was 77.10% (95% CI: 33.55 to 
100.0%) for intramuscular/intravenous naloxone. 
The comparison of the success rate of naloxone 
therapy in improving the level of consciousness 
between the two groups showed no significant 
differences (OR=1.33; 95% CI: 0.02 to 87.55; 
P=0.894); (Table 3). 
 The need for a rescue dose of naloxone to 
manage opioid overdose 
Five studies reported the need for a rescue dose of 
naloxone in the management of opioid overdose. 
Their findings indicated that, in 33.26% (95% CI: 
21.60 to 46.02%) of the cases, there is a need for a 
rescue dose after intranasal naloxone 
administration. This rate was 17.74% (95% CI: 
7.37 to 31.19%) in the intramuscular/intravenous 
group. A comparison of the two administration 
routes revealed that the odds of needing a rescue 
dose were 2.17 times higher with intranasal 
 
Figure 3: The success rate of intranasal (A) and intramuscular/intravenous naloxone (B) in the treatment of opioid overdose. There is 
no significant difference between intranasal and intramuscular/intravenous naloxone success rates (C) (P=0.98). The onset of action 
of intranasal naloxone was slightly longer than intramuscular/intravenous naloxone (D). OR: Odds ratio; SMD: Standardized mean 
difference. 
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naloxone than the intravenous/intramuscular 
route (OR=2.17; 95% CI: 1.53 to 3.09; P<0.0001); 
(Table 3). 
 A comparison of the incidence of naloxone 
side-effects in intranasal versus 
intramuscular/intravenous administration  
The analyses revealed that intranasal naloxone 
administration does not cause any major 
complications (Prevalence=0.00%; 95% CI: 0.00 to 
0.51%). In the reviewed literature, only one serious 
complication was reported for 
intramuscular/intravenous naloxone, including 
one case of grand mal epileptic seizure following 
intramuscular administration (Prevalence=0.05%; 
95% CI: 0.00 to 0.75%). The prevalence of serious 
complications did not differ significantly between 
the two administration routes (OR=1.18; 95% CI: 
0.38 to 3.69; P=0.777). All the side-effects of 
naloxone reported in the articles are considered 
minor. The prevalence of these side-effects was 
7.43% (95% CI: 1.26 to 17.43%) in the intranasal 
naloxone group. The rate of these complications 
was 13.50% (95% CI: 1.59 to 33.33%) in the 
intramuscular/intravenous naloxone group. There 
was no difference between the intranasal naloxone 
groups and intramuscular/intravenous naloxone 
groups (OR=0.64; 95% CI: 0.17 to 2.34; P=0.497) in 
terms of the prevalence of these mild side-effects 
(Table 3).  
DISCUSSION  
The present meta-analysis summarized the 
evidence on the efficacy of intranasal naloxone 
compared with intramuscular/intravenous 
naloxone in improving opioid overdose 
complications in pre-hospital settings. The findings 
demonstrated that intranasal naloxone is as 
effective as intramuscular/intravenous naloxone 
in the pre-hospital management of opioid overdose 
complications. Intranasal naloxone aids in 
restoring the patients’ spontaneous respiration 
and increases their consciousness level. The 
administration of intranasal naloxone was also 
found to cause no serious side-effects and all the 
reported complications were mild. Nevertheless, 
intranasal naloxone has a somewhat longer onset 
of action than intramuscular/intravenous 
naloxone. In addition, intranasal naloxone 
administration requires higher rescue doses 
compared to the other routes of administration. 
Overall, it seems that intranasal naloxone can be an 
acceptable substitute for the 
intramuscular/intravenous form in the 
management of opioid overdose in pre-hospital 
settings. 
Only one case of grand mal seizure was reported as 
a serious complication of intramuscular naloxone 
injection. Other side-effects were chiefly minor and 
consisted of nausea, vomiting, agitation, headaches 
and diaphoresis, which are mostly related to the 
withdrawal syndrome. Intranasal naloxone 
therefore appears to be a safe medication for use in 
pre-hospital settings.  
The patients’ response time (i.e. onset of action) 
was slightly prolonged with the intranasal form of 
naloxone. With a close inspection of the studies, 
however, the difference showed to be only one to 
two minutes. Moreover, the SMD obtained in the 
Table 3: The subgroup analysis of intranasal versus intramuscular/intravenous naloxone administration in the management of opioid 
overdose in prehospital settings 
Variable Heterogeneity Effect size 95% CI P 
Spontaneous respiration (success rate, %)     
Intranasal  96.6% (p<0.0001) 93.63 60.17 to 100.0 <0.0001 
Intramuscular/intravenous 91.9% (p<0.0001) 96.93 81.11 to 100.0 <0.0001 
Difference among the subgroups 0.0% (p=0.760) OR=0.42 95% CI: 0.21 to 0.85; p=0.016 
Improved consciousness (success rate, %)     
Intranasal  96.0% (p<0.0001) 83.95 47.85 to 100.0 <0.0001 
Intramuscular/intravenous 97.2% (p<0.0001) 77.10 33.55 to 100.0 <0.0001 
Difference among the subgroups 91.4% (p<0.0001) OR=1.33 95% CI: 0.02 to 87.55; p=0.894 
Need for rescue dose (%)     
Intranasal  82.9 (p<0.0001) 33.26 21.60 to 46.02 <0.0001 
Intramuscular/intravenous 90.3% (p<0.0001) 17.74 7.37 to 31.19 <0.0001 
Difference among the subgroups 0.0% (p=0.407) OR=2.17 95% CI: 1.53 to 3.09; p<0.0001 
Major complications (%)     
Intranasal  0.0% (p>0.999) 0.00 0.00 to 0.50 <0.0001 
Intramuscular/intravenous 0.0% (p=0.910) 0.05 0.00 to 0.75 <0.0001 
Difference among the subgroups 0.0% (p=0.407) OR=1.18; 95% CI: 0.38 to 3.69; p=0.777 
Minor complications (%)     
Intranasal  86.1 (p<0.0001) 7.43 1.26 to 17.43 <0.0001 
Intramuscular/intravenous 94.2% (p<0.0001) 13.50 1.59 to 33.33 <0.0001 
Difference among the subgroups 71.3% (p=0.015) OR=0.64; 95% CI: 0.17 to 2.34; p=0.497 
CI: Confidence interval; OR: Odds ratio 
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meta-analysis of the records was rather weak and 
negligible. 
This study also revealed that intranasal naloxone 
quickly restores normal respiration in 93.63% of 
the cases, while this rate was 96.3% for the 
intravenous form. Although this 3.3% difference is 
statistically significant, it can be clinically ignored. 
The need for a rescue dose of naloxone for opioid 
overdose was up to 2.2 times higher with 
intranasal administration compared to 
intravenous administration, which could be 
construed as a limitation for intranasal naloxone. 
Nevertheless, since intravenous naloxone does not 
require intravenous access and its re-
administration does not cause serious 
complications, this limitation is not major enough 
to prevent its use. 
The review of literature showed two similar 
systematic reviews and meta-analyses on the 
effectiveness of naloxone administration in 
controlling opioid overdose symptoms in pre-
hospital settings. Compared to the findings of the 
present study, a systematic review by Chou et al. in 
2017 indicated that high-dose intranasal naloxone 
may have a similar efficacy to intramuscular 
naloxone (without performing a meta-analysis). 
This study demonstrated that the complications of 
high-dose intranasal naloxone are similar to those 
of intramuscular naloxone (5). Nonetheless, the 
failure to perform a meta-analysis or review 
Embase were major weaknesses of this article. 
Also, another systematic review in 2018 with a 
search carried out in PubMed, Ovid and Google 
Scholar revealed the lack of a consensus over the 
best route for the administration of naloxone for 
opioid overdose management in pre-hospital 
settings. The cited study was also a qualitative 
study of clinical trials and its findings were based 
on an incomplete database search (26). In contrast, 
the present study used an analytical approach to 
show that intranasal naloxone administration is as 
effective as injectable naloxone in the management 
of opioid overdose complications. 
Limitations and strengths 
The present study conducted an extensive search 
of electronic resources, contacted the authors and 
searched relevant webpages to obtain the 
maximum number of articles and also examined 
gray literature. The lack of publication bias is 
another strength of this study. The heterogeneity in 
the analyses was one of the study’s limitations. The 
non-blinded observers in some of the included 
studies was another limitation of this study, as non-
blinded observers may cause bias in the findings. 
CONCLUSION 
The present meta-analysis demonstrated that the 
therapeutic success rates of 
intramuscular/intravenous naloxone and 
intranasal naloxone are similar and both routes do 
not cause any serious complications. Therefore, 
intranasal naloxone may be a suitable alternative 
to intramuscular/intravenous naloxone in pre-
hospital settings in the treatment of opioid 
overdose. 
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Appendix 1: Medline search query 
Search terms 
1. “Emergency Medical Services”[mh] OR “Emergency Health Service”[tiab] OR “Emergency Care”[tiab] OR “Prehospital 
Medication”[tiab] OR “Prehospital Care”[tiab] OR “Prehospital”[tiab] OR “Emergency Services, Medical”[tiab] OR “Emergency 
Service, Medical”[tiab] OR “Medical Emergency Service”[tiab] OR “Medical Emergency Services”[tiab] OR “Service, Medical 
Emergency”[tiab] OR “Services, Medical Emergency”[tiab] OR “Medical Services, Emergency”[tiab] OR “Emergency Medical 
Service”[tiab] OR “Medical Service, Emergency”[tiab] OR “Service, Emergency Medical”[tiab] OR “Services, Emergency 
Medical”[tiab] OR “Prehospital Emergency Care”[tiab] OR “Emergency Care, Prehospital”[tiab] OR “Emergicenters”[tiab] OR 
“Emergicenter”[tiab] OR “Emergency Care”[tiab] OR “Emergency Health Services”[tiab] OR “Emergency Health Service”[tiab] 
OR “Health Service, Emergency”[tiab] OR “Health Services, Emergency”[tiab] OR “Service, Emergency Health”[tiab] OR 
“Services, Emergency Health”[tiab] 
2. “Drug Overdose”[mh] OR “Substance-Related Disorders“[mh] OR “Analgesics, Opioid”[mh] OR “Opioid-Related 
Disorders”[mh] OR “Heroin Dependence”[mh] OR “Morphine Dependence”[mh] OR “Opium Dependence”[mh] OR “Drug 
Overdose”[tiab] OR “Substance-Related Disorders”[tiab] OR “Analgesics, Opioid”[tiab] OR “Opioid-Related Disorders”[tiab] 
OR “Heroin Dependence”[tiab] OR “Morphine Dependence”[tiab] OR “Opium Dependence”[tiab] OR “Drug Overdoses”[tiab] 
OR “Overdose, Drug”[tiab] OR “Overdoses, Drug”[tiab] OR “Drug Overdose”[tiab] OR “Drug Abuse”[tiab] OR “Abuse, 
Drug”[tiab] OR “Drug Dependence”[tiab] OR “Dependence, Drug”[tiab] OR “Drug Addiction”[tiab] OR “Addiction, Drug”[tiab] 
OR “Substance Use Disorders”[tiab] OR “Disorder, Substance Use”[tiab] OR “Substance Use Disorder”[tiab] OR “Drug Use 
Disorders”[tiab] OR “Disorder, Drug Use”[tiab] OR “Drug Use Disorder”[tiab] OR “Organic Mental Disorders, Substance-
Induced”[tiab] OR “Organic Mental Disorders, Substance Induced”[tiab] OR “Substance Abuse”[tiab] OR “Abuse, 
Substance”[tiab] OR “Abuses, Substance”[tiab] OR “Substance Abuses”[tiab] OR “Substance Dependence”[tiab] OR 
“Dependence, Substance”[tiab] OR “Substance Addiction”[tiab] OR “Addiction, Substance”[tiab] OR “Prescription Drug 
Abuse”[tiab] OR “Abuse, Prescription Drug”[tiab] OR “Drug Abuse, Prescription”[tiab] OR “Drug Habituation”[tiab] OR 
“Habituation, Drug”[tiab] OR “Opioid Related Disorders”[tiab] OR “Opioid-Related Disorder”[tiab] OR “Addiction, 
Opioid”[tiab] OR “Opioid Addiction”[tiab] OR “Addictions, Opioid”[tiab] OR “Opioid Addictions”[tiab] OR “Opioid 
Dependence”[tiab] OR “Dependences, Opioid”[tiab] OR “Opioid Dependences”[tiab] OR “Dependence, Opioid”[tiab] OR 
“Opioid Abuse”[tiab] OR “Abuse, Opioid”[tiab] OR “Abuses, Opioid”[tiab] OR “Opioid Abuses”[tiab] OR “Narcotic Abuse”[tiab] 
OR “Abuse, Narcotic”[tiab] OR “Abuses, Narcotic”[tiab] OR “Narcotic Abuses”[tiab] OR “Opiate Abuse”[tiab] OR “Abuse, 
Opiate”[tiab] OR “Abuses, Opiate”[tiab] OR “Opiate Abuses”[tiab] OR “Opiate Dependence”[tiab] OR “Dependence, 
Opiate”[tiab] OR “Opiate Addiction”[tiab] OR “Addiction, Opiate”[tiab] OR “Narcotic Dependence”[tiab] OR “Dependence, 
Narcotic”[tiab] OR “Dependences, Narcotic”[tiab] OR “Narcotic Dependences”[tiab] OR “Narcotic Addiction”[tiab] OR 
“Addiction, Narcotic”[tiab] OR “Addictions, Narcotic”[tiab] OR “Narcotic Addictions”[tiab] OR “Dependence, Heroin”[tiab] OR 
“Heroin Addiction”[tiab] OR “Addiction, Heroin”[tiab] OR “Heroin Abuse”[tiab] OR “Abuse, Heroin”[tiab] OR “Heroin 
Smoking”[tiab] OR “Heroin Smokings”[tiab] OR “Smoking, Heroin”[tiab] OR “Dependence, Morphine”[tiab] OR “Morphine 
Addiction”[tiab] OR “Addiction, Morphine”[tiab] OR “Morphine Abuse”[tiab] OR “Abuse, Morphine”[tiab] OR “Dependence, 
Opium”[tiab] OR “Opium Addiction”[tiab] OR “Addiction, Opium”[tiab] OR “Opium Use”[tiab] OR “Opium Uses”[tiab] OR “Use, 
Opium”[tiab] OR “Uses, Opium”[tiab] OR “Opium Abuse”[tiab] OR “Abuse, Opium”[tiab] OR “Abuses, Opium”[tiab] OR “Opium 
Abuses”[tiab] OR “Opium Smoking”[tiab] OR “Smoking, Opium”[tiab]  
3. “Narcotic Antagonists”[mh] OR “Naloxone”[mh] OR “Narcotic Antagonists”[tiab] OR “Naloxone”[tiab] OR “Antagonists, 
Narcotic”[tiab] OR “Opioid Receptor Antagonists”[tiab] OR “Antagonists, Opioid Receptor”[tiab] OR “Receptor Antagonists, 
Opioid”[tiab] OR “Opioid Antagonists”[tiab] OR “Antagonists, Opioid”[tiab] OR “Competitive Opioid Antagonists”[tiab] OR 
“Antagonists, Competitive Opioid”[tiab] OR “Opioid Antagonists, Competitive”[tiab] OR “Opioid Reversal Agents”[tiab] OR 
“Agents, Opioid Reversal”[tiab] OR “Nalone”[tiab] OR “Naloxon Curamed”[tiab] OR “Curamed, Naloxon”[tiab] OR “Naloxon-
Ratiopharm”[tiab] OR “Naloxon Ratiopharm”[tiab] OR “Naloxone Abello”[tiab] OR “Abello, Naloxone”[tiab] OR “Naloxone 
Hydrochloride”[tiab] OR “Hydrochloride, Naloxone”[tiab] OR “Naloxone Hydrochloride Dihydride”[tiab] OR “Dihydride, 
Naloxone Hydrochloride”[tiab] OR “Hydrochloride Dihydride, Naloxone”[tiab] OR “Naloxone Hydrochloride, (5 beta,9 
alpha,13 alpha,14 alpha)-Isomer”[tiab] OR “Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer”[tiab] OR “Narcan”[tiab] OR 
“Narcanti”[tiab] OR “MRZ-2593”[tiab] OR “MRZ 2593”[tiab] OR “MRZ2593”[tiab] OR “MRZ 2593-Br”[tiab] OR “MRZ 2593 
Br”[tiab] OR “MRZ 2593Br”[tiab] OR “Naloxone Hydrobromide”[tiab] OR “Hydrobromide, Naloxone”[tiab] 
4. #1 AND #2 AND #3 
 
